SY
View Simon's Contact Info for Free. Sign Up and Get 50 Free Contacts Per Month.Get Started for Free
Work Experience
N/A
Aug 2023 - Present · 1 years and 4 months
N/A
May 2018 - Sep 2018 · 4 months
N/A
Oct 2013 - Jul 2015 · 1 years and 9 months
Company Details
1001-5000 Employees
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. Review our Community Guidelines: https://bit.ly/3L8M8hx *in collaboration with AbbVie
Year Founded
1992
Social Media
LinkedinFacebookTwitter
Industry
Biotechnology Research, Bulk Pharmaceuticals, Pharmaceuticals, Chemicals, Bulk Drugs, Over-The-Counter (OTC) Pharmaceutical Contract Packaging Services, Drugs, Vitamins & Supplements, Other, Over-The-Counter (OTC), Proprietary, Packaged Medicines, Drugs & Remedies, Laxatives
HQ Location
San Diego, California, US
Keywords
Movement DisordersCNSNeurologyEndocrinologyand Endocrinologyviable treatmentads and marketingantipsychotic medicationspipeline chartsodium channel
Discover More About Cleveland Clinic

Find verified contacts of Simon Yeung in seconds from 700M people profiles. Start now!

No Credit Card Needed. By signing up, you understand and agree to Futern's Terms and Policy.